KPTI News - Candlesense

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:KPTI) NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced ...

Compensation

7 days ago

KP Tissue declares a Quarterly Dividend of $0.18 per Common Share

NOT FOR DISTRIBUTION IN THE U.S.A. OR OVER U.S. WIRE SERVICES

Are there any upcoming corporate events (e.g., earnings releases, M&A activity) that could influence the dividend’s impact on the stock price? What are the potential risks (e.g., cash flow constraints, debt levels) that could affect future dividend payments? How does KPTI’s dividend yield compare to its main competitors in the same sector?

Dividends

28 days ago

KP Tissue Releases Second Quarter 2025 Financial Results

Strong profitability with Memphis investment to drive efficiency and support growing U.S. business Strong profitability with Memphis investment to drive efficiency and support growing U.S. business

What are the implications of this results for KP Tissue's long‑term growth outlook and competitive positioning in the U.S. market? How does this earnings release influence the stock's valuation multiples (e.g., P/E, EV/EBITDA) compared to historical levels? What is the projected impact of the Memphis investment on KP Tissue's cash flow and capital allocation strategy?

Earnings

28 days ago